Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP TMS SA : EDAP Reports 2018 Third Quarter Results
Generated revenue growth of more than 14% as compared to the third quarter of 2017 Continued geographic expansion of Focal One with installations in Brazil and South Korea Since receiving FDA clearance for Focal One in June 2018 , progressed through the lengthy capital equipment sales cycle with
View HTML
Toggle Summary EDAP TMS SA : EDAP TMS SA to Announce Third Quarter 2018 Financial Results on Wednesday, November 14
LYON, France , November 6, 2018 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the third quarter and nine months ended September 30, 2018 , after the close of the financial markets on Wednesday, November 14,
View HTML
Toggle Summary EDAP TMS SA : Urologic Oncologists from Top US Teaching Hospitals Gather in Montreal to Learn Advanced Prostate Sparing Medical Procedure
MONTREAL, QUEBEC - OCTOBER 24, 2018 - Urologists, uro-oncologists and urology department chairs from renowned American universities will spend a day - October 25, 2018 -- at Jewish General Hospital , a McGill University teaching hospital, where they will learn to perform a more precise outpatient
View HTML
Toggle Summary EDAP TMS SA : EDAP Announces Expiration of Tranche of Outstanding Warrants
   Warrants for Approximately 3.3 Million Ordinary Shares in the Form of American Depository Shares Expired on October 14, 2018 LYON, France , October 15, 2018 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in therapeutic ultrasound, announced today that warrants for approximately
View HTML
Toggle Summary EDAP TMS SA : EDAP Announces the Installation of a Third Focal One® HIFU Device in Brazil
HIFU Prostate Cancer Treatments Successfully Performed at Albert Einstein Hospital , Sao Paulo LYON, France , September 27, 2018 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the installation of the third Focal One device in Brazil at the renowned Albert
View HTML
Toggle Summary EDAP TMS SA : Houston Methodist Medical Center Research Study Sheds Positive Light on Use of HIFU for Localized Prostate Cancer
AUSTIN, TX - LYON, France , September 26, 2018 - EDAP TMS (Nasdaq: EDAP) today announced the results of a study conducted at Houston Methodist Medical Center in Houston, TX that showed High Intensity Focused Ultrasound (HIFU) to be safe and effective, with oncologic control for prostate cancer
View HTML
Toggle Summary EDAP TMS SA : EDAP announces Installation of First Focal One HIFU device in South Korea
Successful HIFU Treatments Performed in Seoul National University Bundang Hospital LYON, France , September 20, 2018 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the installation of the first Focal One device in South Korea , at the renowned Seoul
View HTML
Toggle Summary EDAP TMS SA : EDAP Reports 2018 Second Quarter Results
Receives FDA clearance for novel Focal One device for prostate tissue ablation LYON, France , August 29, 2018 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in therapeutic ultrasound, announced today financial results for the second quarter of 2018 and provided a strategic and
View HTML
Toggle Summary EDAP TMS SA : EDAP TMS SA to Announce Second Quarter 2018 Financial Results on Thursday, August 30
LYON, France , July 24, 2018 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the second quarter and six months ended June 30, 2018 , before the open of the financial markets on Thursday, August 30, 2018 .
View HTML
Toggle Summary EDAP TMS SA : EDAP Announces FDA Clearance for Focal One®
AUSTIN, TX , LYON, FRANCE -- JUNE 7, 2018 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in therapeutic ultrasound, today announced that it has received 510(k) clearance from the US Food and Drug Administration ( FDA ) for its Focal One device for the ablation of prostate tissue. 
View HTML